Bacteriophages are viruses that specifically target and destroy bacteria while leaving human and animal cells unharmed. Due to this distinctive capability, scientists consider them as a promising alternative for combating antibiotic-resistant bacterial infections. Currently, no phage therapy products have been approved for human use in either the EU or the United States.
The company we are profiling today is Armata Pharmaceuticals (ARMP), a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections. Its phage product candidates include AP-PA02 and AP-SA02.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.